BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15790431)

  • 1. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
    Fujiwara K; Markman M; Morgan M; Coleman RL
    Gynecol Oncol; 2005 Apr; 97(1):10-5. PubMed ID: 15790431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counterpoint: Intraperitoneal chemotherapy: an investigational treatment in ovarian cancer.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Nov; 2(6):555-60. PubMed ID: 19780299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
    Fujiwara K; Sakuragi N; Suzuki S; Yoshida N; Maehata K; Nishiya M; Koshida T; Sawai H; Aotani E; Kohno I
    Gynecol Oncol; 2003 Sep; 90(3):637-43. PubMed ID: 13678738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer.
    Polyzos A; Tsavaris N; Kosmas C; Giannikos L; Katsikas M; Kalahanis N; Karatzas G; Christodoulou K; Giannakopoulos K; Stamatiadis D; Katsilambros N
    Oncology; 1999; 56(4):291-6. PubMed ID: 10343192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
    Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
    Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
    Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
    Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
    Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
    J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can carboplatin replace cisplatin for intraperitoneal use?
    Fujiwara K
    Int J Gynecol Cancer; 2008; 18 Suppl 1():29-32. PubMed ID: 18336396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Monk BJ; Chan JK
    Ann Oncol; 2017 Nov; 28(suppl_8):viii40-viii45. PubMed ID: 29232474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.